peoplePerson
Helena A. Yu
Mapped how EGFR-mutant lung cancers resist osimertinib and led the HER3-directed ADC trials that followed.
Characterised acquired resistance mechanisms to EGFR inhibitors, including T790M and histologic transformation, and was a principal investigator of the HERTHENA-Lung01 patritumab deruxtecan study.
Role
Medical Oncologist, Thoracic Oncology Service
Institution
Specialisms
EGFR-mutant lung cancerResistance mechanismsADCs in lung cancer
Profiles
| Title | Journal | Year |
|---|---|---|
| Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers | Clinical Cancer Research | 2013 |
| HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC after EGFR TKI therapy and platinum-based chemotherapy | Journal of Clinical Oncology | 2023 |
Pages like this
not linked directly; found by shared links- TrialHERTHENA-Lung02
Shares Patritumab deruxtecan, HER3, Non-small-cell lung cancer.
- TrialLAURA
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- PairingEGFR TKI → ADC on progression
Shares Patritumab deruxtecan, Osimertinib, Non-small-cell lung cancer.
- PersonJean-Charles Soria
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- IdeaBlock the survival signals the tumour's neighbours provide
Shares Patritumab deruxtecan, HER3.
- PersonJohn V. Heymach
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- IdeactDNA-guided dose holidays for lung cancer targeted therapy
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- IdeaAdd a drug when the blood test turns, without stopping the one that works
Shares Osimertinib, EGFR, Non-small-cell lung cancer.